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ABSTRACT

Methods for melanoma treatment and prevention with selec

tive nitric oxide synthase inhibitor compounds and related
pharmaceutical compositions, alone or in conjunction with
one or more other melanoma therapies.
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1.
SPECIFICNNOS INHIBITORS FOR THE
THERAPY AND PREVENTION OF HUMAN
MELANOMA

This application is a divisional of and claims prior benefit
of application Ser. No. 13/348,819 filed Jan. 12, 2012 and
issued as U.S. Pat. No. 8,642,282 on Feb. 4, 2014, and appli

5

cation Ser. No. 61/461,029 filed Jan. 12, 2011—each of

which is incorporated herein by reference in its entirety.
This invention was made with government Support under
GM049725 awarded by the National Institutes of Health. The
government has certain rights in the invention.

10

variants derived from the same melanoma cell line also has

BACKGROUND OF THE INVENTION
15

Ultraviolet (UV) radiation has been implicated as a major
environmental contributor to the development of most cuta
neous melanomas. Sunscreens and Sun awareness behavior

have been used for the prevention of cutaneous melanoma,
but their clinical utility remains mixed. The mechanistic role
of UV radiation in melanomagenesis needs to be more com
prehensively defined. However, it is known that in human
skin, UV radiation not only generates reactive oxygen species
(ROS), but also produces a marked increase of nitric oxide
(NO). (Russo P. A., Halliday G. M. Inhibition of nitric oxide
and reactive oxygen species production improves the ability
of a Sunscreen to protect from Sunburn, immunosuppression
and photocarcinogenesis. Br. J. Dermatol. 2006: 155:408
15). While the contributions of ROS to melanomagenesis
have been extensively studied, characterizations of effects of

25

SUMMARY OF THE INVENTION

35

40

45

In light of the foregoing, it is an object of the present
invention to provide one or more methods for the treatment
and/or prevention of UV radiation-induced melanoma,
thereby addressing various concerns relating to the prior art,
including those outlined above. It will be understood by those
skilled in the art that one or more aspects of this invention can
meet certain objectives, while one or more other aspects can
meet certain other objectives. Each objective may not apply
equally, in all its respects, to every aspect of this invention. As
such, the following objects can be viewed in the alternative
with respect to any one aspect of this invention.
It can be an object of the present invention to extend inhi
bition of nitric oxide synthase inhibitors to the attenuation of
cellular alterations induced by UV radiation.
It can be another object of the present invention to target
neuronal nitric oxide synthase with one or more specific
inhibitor compounds, including but not limited to those illus
trated herein, to diminish nitric oxide stress in human mela
Oa.

50

Oxide. 2008; 19:133-7: Massi D., De Nisi M. C., FranchiA.,
Mourmouras V., Baroni G., Panelos J., et al. Inducible nitric

oxide synthase expression in melanoma: implications in lym
phangiogenesis. Mod. Pathol. 2009; 22:21-30; Ekmekcioglu
S., Ellerhorst J. A., Prieto V. G., Johnson M. M., Broemeling
L. D., Grimm E. A. Tumor iNOS predicts poor survival for
stage III melanoma patients. Int. J. Cancer. 2006: 119:861-6.)
The NOS family comprises inducible NOS (iNOS), endot
helial NOS (eNOS), and neuronal NOS (nNOS), the latter of
which is expressed mainly in neural tissue. Previous studies
have largely focused on iNOS and its inhibitors, which exhib
ited promising chemopreventive activities in skin carcino
genesis but limited anti-melanoma potential. As melanocytes
originate from the neural crest and have many gene expres
sion characteristics similar to neural cells, nNOS may play a
unique role in regulating NO levels in melanocytes. In con
trast to iNOS-mediated generation of high levels of NO.

been reported. A recent clinical epidemiologic study investi
gated the role of polymorphisms of nNOS as related to out
come and demonstrated that certain nNOS (but not iNOS)
genotypes were associated with an increased risk of cutane
ous melanoma. (Li C. Hu Z., Liu Z. Wang L. E., Gershen
wald J. E., Lee J. E., et al. Polymorphisms of the neuronal and
inducible nitric oxide synthase genes and the risk of cutane
ous melanoma: a case-control study. Cancer. 2007: 109:1570
8.) Moreover, this study also identified significant interac
tions of the combined nNOS genotypes and moles and the
lifetime number of blistering sunburns.
With increasing evidence of the role of nNOS in melanoma
progression, the art is likewise concerned with and directed to
a search for specific nNOS inhibitors and related methods of
melanoma treatment and prevention.

30

NO stress and its detailed molecular mechanisms have been
limited.

NO, produced from L-arginine by nitric oxide synthase
(NOS), leads to highly reactive oxidants such as peroxyni
trite, resulting in DNA damage even in physiologically rel
evant ranges of NO. In the skin, NO-mediated signaling also
contributes to UV-induced melanogenesis and pigmentation.
(Romero-Graillet C., Aberdam E. Clement M., Ortonne J. P.
Ballotti R. Nitric oxide produced by ultraviolet-irradiated
keratinocytes stimulates melanogenesis.J. Clin. Invest. 1997:
99:635-42.) Large quantities of NO have been detected in
many types of cancer tissues, and the role of NO in carcino
genesis, tumor growth and metastasis has been well docu
mented in skin cancer and other tumors. Constitutive produc
tion of NO in melanoma resulted in increased proliferation,
impaired immune response, and lymphangiogenesis, associ
ated with poor survival in patients. (Grimm E. A., Ellerhorst
J., Tang C.H., Ekmekcioglu S. Constitutive intracellular pro
duction of iNOS and NO in human melanoma: possible role
in regulation of growth and resistance to apoptosis. Nitric

2
nNOS produces lower levels of NO and mediates direct cel
lular effects such as neuromodulation. In a 1999 study, a
progressive increase of nNOS expression was evident over
the course of melanoma progression, Suggesting that the de
novo expression of nNOS may be a marker for an early stage
of melanoma. (Ahmed B. Van Den Oord J. J. Expression of
the neuronal isoform of nitric oxide synthase (nNOS) and its
inhibitor, protein inhibitor ofnNOS, in pigment cell lesions of
the skin. Br. J. Dermatol. 1999; 141:12-9.) Differential
expression of nNOS in tumorigenic and non-tumorigenic

55

It can be another object, alone or in conjunction with one or
more of the preceding objectives, to provide one or more
nNOS inhibitor compounds and/or related compositions to
affect and/or inhibit induction of nNOS expression and/or
melanoma cell proliferation.
Other objects, features, benefits and advantages of the
present invention will be apparent from this Summary and its
descriptions of certain embodiments, and will be readily
apparent to those skilled in the art of treatment and prevention
of melanoma, related disease states and indications thereof.

60

Such objects, features, benefits and advantages will be appar
ent from the above as taken into conjunction with the accom
panying examples, data, figures and all reasonable inferences
to be drawn therefrom, alone or with consideration of the

65

references cited or incorporated herein.
In part, the present invention can be directed to a method
for affecting and/or inhibiting a nitric oxide synthase. Such a
method can comprise contacting, in vivo or in vitro, a human

US 9,090,589 B2
3
melanocyte or melanoma cell expressing nitric oxide Syn
thase with an effective amount of a compound selected from
compounds of a formula
R2
N

21

"t

HN

N

N

71

R3
10

wherein R can be selected from H. halogen, alkyl (e.g., CH).
and substituted alkyl (e.g., CF) moieties; R can be selected
from H. alkyl, aryl, amino, hydroxy, Substituted aryl or a
substituted alkyl (e.g., but not limited to haloalkyl, arylalkyl,
aminoalkyl or hydroxyalkyl) moieties; Z can be selected from
NH, O, and NHCO; and R can be selected from alkyl, sub
stituted alkyl, hydroxyalkyl, substituted hydroxyalkyl, aryla
lkylaminoalkyl, Substituted arylalkylaminoalkyl, arylalky
loxaalkyl, Substituted arylalkyloxaalkyl, arylalkyl,
substituted arylalkyl, arylalkylamidoalkyl (where the amido
group is either NHCO or CONH), substituted arylalkylami
doalkyl, aminoalkyl, and Substituted aminoalkyl moieties
(e.g., but not limited to linear or cyclic alkylamine), where
Such substituents can include but are not limited to halogen
(e.g., fluoro, chloro, etc.) Substituent(s).
In certain embodiments, R can be selected from H or
various alkyl moieties. In a Subset of Such embodiments, R
can be H, and Z can be selected from NH and O with R.
selected from phenylethyl (or phenylmethylene)aminoalkyl
and substituted (e.g., without limitation fluoro-substituted)
phenylethyl(or phenylmethylene)aminoalkyl moieties. In
certain other embodiments, R can be selected from H and
methyl moieties, and R. R. Zand Y can independently vary

above, Such as and without limitation, of a formula
15

N
H
2

25

Increased total NOS activities in melanoma cell lines com
40

50

55

R2
N
60

z1N1

N

pared to immortalized MEL-ST melanocytes. Results are
expressed in folds of change standardized by Mel-ST cells for
3 biologic replicates. *, p<0.05 compared to Mel-ST cells.
FIGS. 2A-H. nNOS expression is elevated in melanoma
compared to normal melanocytes. (A) Immunoblotting assay
of human primary melanocytes and melanoma cell lines; (B)
Immunoblotting assay of mouse melanoma cell lines
(F428OB, F5061 and F5127) and mouse melanocytes
(MMC). (C) Immunohistochemistry analysis of nNOS
expression levels using melanoma tissue array. Positive cells
were visualized by light microscope and at least 10 highlight
fields of each sample were examined. (D) Increased nNOS
stainings in melanoma biopsies were significantly correlated
with disease stages. IHC staining score was determined by the
average percentage of cells positive for nNOS: 0, 0-5%; 1,
6-30%; 2, 31-59%; 3, >60%. The number of samples in
normal, T2NOMO, T3NOMO and T4NOMO were 23, 3, 9 and

10 respectively. *, p<0.05 compared to normal skin tissue.
(E-F) nNOS expression is markedly increased by UVA (D) or
UVB (E) radiation in human melanoma cells. The repre
sented data was done in win3211 cells. (G-H) bFGF (10
ng/ml) treatment induced nNOS expression in normal Cau
casian melanocytes, but DETA/NO and UVB produced no
increase of nNOS levels.

--R4

FIGS. 3A-B. (A) nNOS depletion in melanoma associated
with down-regulation of genes involved in proliferation and

21

wherein R can be selected from H. halogen, methyl and
Substituted methyl (e.g., fluoro Substituted, etc.) moieties; R.
can be selected from H, alkyl and substituted alkyl (e.g.,

cells. (C) Both UVA (3 J/cm) and UVB (25 mJ/cm) radia

tion increased NO levels in primary melanomawm3211 cells.
Results represent the means--/-SDs of three replicates. (D)

of a formula

H2NT
N

and contacting a cellular medium, expressing or capable of
expressing neuronal nitric oxide synthase, with an effective
amount of Such a compound. The effect of Such a compound
on nNOS expression can be determined, as understood by
those skilled in the art, through histological studies and
immunoblotting assays of the sort described herein.

35

tion with a method or medicament of this invention.

N

F

FIGS. 1A-D. (A) DETA/NO treatment stimulates melano
cyte proliferation. The photos represent foci formed after 10
weeks. (B) NO stress generated by DETA/NO or L-arginine
enhanced melanoma proliferation, more evident in metastatic

resolved or are diastereomers, from which cis and/or trans

In part, the present invention can also be directed to a
method of affecting, inhibiting and/or reducing NO produc
tion, such as can be induced by UV-radiation. Such a method
can comprise contacting a cellular medium expressing or
capable of expressing neuronal nitric oxide synthase with an
effective amount of a selective inhibitor compound of the sort
described herein, such as and without limitation compounds

N

BRIEF DESCRIPTION OF THE DRAWINGS

are available as racemic mixtures from which isomers can be

isomers can be separated. Accordingly, any Stereocenter can
be (S) or (R) with respect to any other stereocenter(s). Further,
it will be understood by those skilled in the art that the com
pounds of this invention can comprise an acid salt, hydrate
and/or solvate of any such compound. Without limitation,
certain embodiments can be partially or fully protonated,
comprising a primary, secondary and/or tertiary amine,
whereby the counterion(s) can be a conjugate base of a protic
acid. Regardless, any such compound(s) can be provided as
part of a pharmaceutical composition comprising a pharma
ceutically-acceptable carrier component for use in conjunc

"

30

as described elsewhere herein.

Such compounds are without stereochemical limitation. As
illustrated below, such compounds and/or their intermediates

4
fluoro-, amino-, etc.) moieties; Z can be selected from O and
NH; and R can be selected from H, alkyl, substituted alkyl
(e.g., fluoro, chloro, etc.) and halogen (e.g., fluoro, chloro)
moieties. Without limitation, the ethylaminoethyl and/or phe
nyl moieties can be substituted with one or more halo (e.g.,
fluoro and chloro), alkyl and/or haloalkyl (e.g., trifluorom
ethyl) substituents. Regardless, such a compound can be cis
or trans with respect to the stereocenters and present as a salt,
hydrate and/or solvate thereof.
In part, the present invention can also be directed to a
method of affecting and/or inhibiting nNOS expression, such
expression as can be induced by UV-radiation. Such a method
can comprise providing a compound of the sort described

65

metastasis. Metastatic melanoma cells were transfected with

nNOS siRNA and whole cell lysates were collected for
immunoblotting assay. (B) Reduced invasion potential in

US 9,090,589 B2
6
melanoma, studies also demonstrated that iNOS expression
was associated with poor Survival and in predicting distance
metastasis, and specific iNOS inhibitors were shown to
inhibit melanoma growth. However, upon review of the spe

5
nNOS-depleted melanoma cells. The represented data was
from Lu1205 cells. Same changes were also evident in A375
cells.

FIGS. 4A-F. Specific nNOS inhibitor cpd 8 (JI-11). (A)
Docking model of cpd 8 with nNOS protein. (B) cpd 8 sig
nificantly reduced total NOS activities in human melanoma
Lu1205 cells. Spermidine trihydrochloride (ST), 10uM; cpd
8, 1 uM. Results are the means-SD of three biologic repli
cates of a representative experiment. *, p<0.05 compared to
control cells. (C-D) cpd8 inhibited nNOS expression induced
by DETA/NO stress (C) and UVB radiation (D). (E-F)
Elevated proliferation (E) and invasion potential (F) by
DETA/NO stress were also reversed by cpd 8 co-treatment.
FIGS.5A-E. L-Arginine enhanced the invasion and tumor
growth of human melanoma, which is mediated by nNOS/NO
generation. (A) Matrigel Invasion Analysis of melanoma
A375 cells. Elevated invasion potential by L-arginine was
inhibited by cpd 8 (JI-11) co-treatment. (B) Histology of
melanoma growth stimulated by L-arginine in reconstructed
skin equivalents, which were incubated in the absence or
presence of cpd8. The represented samples were stained with
H&E. (C) The lesions occurred in 3-D skin constructs were
stained positive with S-100 antibody. (D) Intracellular NO
level was increased after incubation with L-arginine, which
was markedly diminished by nNOS depletion in A375 cells.
it, p<0.05, compared to control: *, p<0.05, compared to con
trol siRNA/L-arginine. (E) L-Arginine-induced NO genera
tion was only inhibited by nNOS inhibitoricpd8 (JI-11). RES,
resveratrol: CUR, curcumin. ii, p<0.05, compared to control;
* , p<0.05, compared to L-arginine alone.
FIGS. 6A-C. Effects of novel synthesized nNOS inhibitors
on human melanoma cells. (A) Inhibition of UVA radiation
induced intracellular NO generation detected by Griess
reagents. ii, p<0.05 compared to control: *, p<0.05 compared
to UVA-treated sample; (B) Reduced invasion potential of
metastatic melanoma. Bars represented the means of invaded
cells counted in 20 highlight fields and normalized to control
(set as 1.0). *, p<0.05 compared to control. (C) L-arginine

cific iNOS inhibitors tested in these studies, it was noticed

that these compounds actually were not so selective for iNOS

inhibition. For example, the Kyos and Koos value of

10

15

25

30

35

stimulated adhesion of metastatic melanoma A375 cells to

fibroblast monolayer were inhibited by nNOS inhibitors (2
uM). The data represented in the figure is the mean changes of
OD values (control is normalized as 0). *, p<0.05 compared
to DMSO--L-arginine treatment.
FIG. 7. Effects of cpd JI-16 (a homolog of cpd 2) on cell
proliferation in human melanoma cells. MTT colorimetric
assay was employed after 72-hour treatments, and the relative
proliferation rate was represented as fold of control cells.
FIG.8. Representative nNOS inhibitor compounds as can
be used in accordance with one or more non-limiting embodi

40

45

ments of this invention.
DETAILED DESCRIPTION OF CERTAIN
EMBODIMENTS

By way of illustrating certain, non-limiting embodiments
of this invention, correlations can be drawn with respect to
nNOS/NO stress and melanoma progression. For instance, as
demonstrated below, in human melanoma, nNOS expression

50

induced nNOS occurred in a transient, short-duration manner,

55

is sensitive to UV radiation and associated with the increased

generation of intracellular NO, which stimulates proliferation
and invasion. Knockdown of nNOS reduced the metastatic

capacity of melanoma, and similar inhibition was observed
using novel, highly selective nNOS inhibitors. Representa
tive studies relating to this invention show that targeting
nNOS with specific inhibitors can be at least part of an effec
tive strategy for the treatment of melanoma.
Initially, it was observed that iNOS is markedly induced
after UV radiation and sunburn; that it plays an important role
in carcinogenesis and skin tumor development has been well
documented in many human and animal studies. In human

1,3-phenylene-bis(1.2-ethanediyl)bisisothiourea (PBIT) is
19 nM and 29 nM respectively, indicating the iNOS selectiv
ity overnNOS is only 1.5 fold—suggesting that the reduction
of melanoma growth caused by these compounds may not be
due solely to iNOS blocking, but could also be related to
nNOS inhibition.
Many chemopreventive agents from nutrients or diet, Such
as resveratrol and curcumin, exhibit potent inhibitory effects
on NO generation. Specifically, modulation of iNOS expres
sion has been observed in a wide range of in vitro and in vivo
studies contributing to their chemopreventive activities.
However, increased intracellular NO generation by L-argin
ine supplementation was not affected at all by either resvera
trol or curcumin in melanoma cells, even up to a concentra
tion of 50 uM. (See, e.g., example 5 and FIG. 5E, below.)
Contrary thereto, nNOS inhibitor cpd 8, at concentrations as
low as 1 uM, efficiently inhibited NO production in mela
noma. Such results indicate that NO generation in melanoma
is predominantly mediated by nNOS rather than iNos. (See,
e.g., example 4 and FIGS. 4A-F, together with example 6 and
FIGS. 6A-C, below.)
A study done with 41 benign nevi and 52 primary malig
nant melanomas showed that iNOS is expressed de novo in
most benign pigment cell lesions, while it plays a less signifi
cant role in Vertical growth phase and in metastatic mela
noma. (Ahmed B. Van Den Oord J. J. Expression of the
inducible isoform of nitric oxide synthase in pigment cell
lesions of the skin. Br. J. Dermatol. 2000: 142:432-40.) By
contrast, the present histological study of melanoma biopsies,
there was a significant trend ofnNOS staining increasing with
disease stage. (See, e.g., example 2 and FIGS. 2A-D, below.)
Such results suggest that nNOS staining may serve as an
adjunct biomarker for melanoma diagnosis—and, that NO
stress mediated by nNOS contributes more toward disease
progression than serving as an initiating early event.
While there has been some disagreement regarding the
relevant roles of UVA and UVB in melanomagenesis, the
present data shows distinct effects of UVA and UVB on
nNOS induction and NO generation, indicating that their
regulatory mechanisms might be different. The large
increases of nNOS expression induced by UVA lasted for at
least 72 hours with significantly elevated intracellular NO
production. (However, one literature study showed that in
human keratinocytes, UVA-mediated NO formation was non
enzymatic and came from "NO-storage in the skin, Suggest
ing the induction of nNOS/NO by UVA might be of specific
importance for melanoma cells.) In contrast to UVA, UVB

60

65

and accordingly, the induction of NO was evident shortly
after UVB and peaked at 4 hours, followed by a sharp drop.
(See, e.g., example 1 and FIGS. 1A-D, below.) Although
similar transient nNOS induction after UVB exposure was
reported in HaCaT kerationcytes, the predominant elevation
of NO levels was mediated by iNOS induction, especially in
the late phase post-UVB (>6 hours). Such observations tend
to suggest that the long-lasting nNOS induction by UVA
might account for delayed chronic responses, and the tran
sient nNOS induction by UVB might contribute to acute
reactions.
L-Arginine is of particular importance in human mela
noma. One reason is that L-Arginine serves as the Substrate
for overexpressed nNOS to generate NO in melanoma cells;
another reason lies in the special amino acid metabolism that

US 9,090,589 B2
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occurs in melanoma. Although in normal tissues arginine is
not an essential amino acid, melanoma depends on an exog
enous Supply of arginine due to the lack of argininosuccinate
synthetase (ASS). Currently, recombinant arginine deimi
nase, an Arg-degrading enzyme, is in Phase II clinical trials
for metastatic melanoma patients. Relating to Such develop
ments, the present data shows that L-arginine significantly
enhances the invasion potential of melanoma cells with
increased NO production and stimulated melanoma over
growth in 3-D skin reconstruct. Knockdown of nNOS (e.g.,
example 3, below) or utilization of specific nNOS inhibitors
reversed the effects of L-arginine in melanoma, Suggesting
that the stimulating effects of L-arginine, at least in part,
result from nNOS-mediated NO stress. (See, e.g., example 5
and FIGS. 5A-C, below.) Accordingly, in accordance with
broader aspects of this invention, combination of L-arginine
deprivation with nNOS inhibition may be used to achieve a
better anti-melanoma efficacy.
Relating to the design of an inhibitor, NOS consists of a
reductase domain, an oxygenase domain, and the Substrate
L-arginine. Although the 3 mammalian NOS isoforms
(iNOS, nNOS, and eNOS) share approximately 50% amino
acid identity, the crystal structures of the oxygenase domains
(where substrate oxidation occurs) showed that the active
sites are nearly identical. (Crane B. R., Arvai A. S., Gachhui
R., Wu C., Ghosh D. K., Getzoff E. D., et al. The structure of
nitric oxide synthase oxygenase domain and inhibitor com
plexes. Science. 1997: 278:425-31.) Until recently, isoform
selective drug design for NOS was a challenging problem.
However, as illustrated below, the structural bases for a group
of highly selective nNOS inhibitors have been successfully
elucidated, leading to the design of more potent drug-like
inhibitors. (See, e.g., Ji H. Li H. Martasek P. Roman L. J.,
Poulos T. L., Silverman R. B. Discovery of highly potent and
selective inhibitors of neuronal nitric oxide synthase by frag
ment hopping.J.Med. Chem. 2009:52:779-97; Silverman R.
B. Design of selective neuronal nitric oxide synthase inhibi
tors for the prevention and treatment of neurodegenerative

10
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instance,

N
H
2.

N
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diseases. Acc. Chem. Res. 2009; 42:439-51, and Ji H., Tan S.,

Igarashi J. Li H., Derrick M., Martasek P. et al. Selective
neuronal nitric oxide synthase inhibitors and the prevention
of cerebral palsy. Ann. Neurol. 2009; 65:209-17.)
As shown through the present studies, potent nNOS inhibi
tors of the sort described herein with distinct K values for
nNOS, iNOS and eNOS efficiently inhibited UVA-induced
NO production and reduced the invasion potential of meta
static melanoma cells. Comparison of their iNOS or nNOS

8
inhibitory potency with observed anti-invasion activities
found no significant correlations; however, a positive regres
sion curve was more evident for nNOS, Suggesting that the
inhibitory effects of nNOS is more related to melanoma inhi
bition compared to that of iNOS and eNOS.
Accordingly, as demonstrated, targeting nNOS/NO with
NOS inhibitors represents an innovative chemopreventive
strategy. The high selectivity of the representative nNOS
inhibitors described hereincan be used to avoid off-target side
effects of the sort that occur after administration of less
selective compounds. With such selective, bio-available and
potent inhibitors, the present NO/nNOS-targeted methods
can be used alone or in conjunction with one or more other
melanoma therapies.
Compounds useful in conjunction with the present meth
ods can be prepared, using synthetic techniques understood
by those skilled in the art made aware of this invention. For

40

as shown in Scheme 1, the synthesis of inhibitor compound 1
(i.e., compound 8, FIG. 8) can begin with Boc-protected
aminopyridine 2 (Delker, D. L.; Ji, H., Li, H.; Jamal, J.; Fang,
J.; Xue, X. Silverman, R. B.; Poulos, T. L. Unexpected Bind
ing Modes of Nitric Oxide Synthase Inhibitors Effective in
the Prevention of Cerebral Palsy, J. Am. Chem. Soc. 2010,
132, 5437-5442.). Alkylheterocycle (e.g., a Boc-protected
2-aminopyridine)3 is treated with two equivalents of n-Bulli,
and the resulting dianion is allowed to react with a Boc
protected pyrrolidine epoxide (4) to generate the trans-alco
hol (5a) in modest yields. The free NH group on the pyridine
ring was further protected with a Bn-protecting group using
NaH followed by BnBr to yield 6 in high yields. The stere
ochemistry of the hydroxyl carbon is inverted by a Mitsunobu
reaction with HOAc (7), then hydrolysis gives (+)-8. The two
enantiomers of 8 are resolved through camphanic ester
derivatives using a Mitsunobu reaction to generate two sepa
rable diastereomers (9a and 9b) in excellent yields. Finally,
the ester linkage of the desired diastereomer is hydrolyzed
using NaCO to provide chiral pyrrolidine precursor 10a in
high yields.

Scheme 1. Synthesis of pyrrollidine precursor 10a
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As shown in Scheme 2, chiral cis-alcohol 10a is treated

under Mitsunobu conditions with DPPA to give trans azide
11. Simultaneous benzyl deprotection and azide reduction by
palladium-catalyzed hydrogenolysis gives the corresponding
chiral amine (12). Reductive amination with aldehyde 14 50
gives the triprotected 13. Deprotection with 4 NHCl in diox
ane gives 1.
Scheme 2. Synthesis of compound 1
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Aldehyde 14 can be prepared as shown in Scheme 3. 2-(3- 35
Fluorophenyl)ethanol can be oxidized with Dess-Martin
periodinane to give 15. Reductive amination with N-(2-hydroxyethyl)benzylamine gives 16. Hydrogenolysis, Boc protection, and Dess-Martin oxidation gives 14 in excellent
yields.
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Scheme 3. Synthesis of aldehyde 14 used in the synthesis of 1
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While the present invention can be illustrated in the context
of compound 1, it will be understood by those skilled in the art
that such methodologies can comprise use of various other
65 compounds and related pharmaceutically-acceptable compo
sitions. Such compounds and related compositions of the sort
described herein and available through the synthetic proce

US 9,090,589 B2
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dures described in U.S. Pat. Nos. 7,470,790 and 7,994,326–

each of which is incorporated herein by reference in its
entirety. Without limitation, a range of compounds varied by
choice of Zand R can be prepared as described in the context
of substructure III, as discussed more fully in the incorporated

5

treatment, and like factors well-known in the medical and

references. Like, as discussed and illustrated in the aforemen

tioned incorporated references, the ring moieties of Substruc
tures I and II can also be varied as discussed therein. Without

limitation, several such compounds selective for inhibition of
nNOS over the other isoforms and useful in conjunction with
the present methodologies are shown in FIG. 8. Such com
pounds can be prepared using synthetic techniques of the sort
illustrated above or in the incorporated references, or through
straight-forward modifications of Such synthetic tech
niques—such modifications as would also be understood by

10

15

those skilled in the art and made aware of this invention—and

are limited only by commercial or synthetic availability of
Suitable starting materials and reagents.
With reference to FIG. 8 (and Table 1, below) representa
tive compounds useful in conjunction with the present meth
ods include but are not limited to:

N'-((3R,4R)-4-((6-amino-4-methylpyridin-2-yl)methyl)
pyrrolidin-3-yl)-N'-(3-fluorophenethyl)ethane-1,2-di
amine (1):
6-(((3S,4S)-1-benzyl-4-((3-phenylpropyl)amino)pyrrolidin
3-yl)methyl)pyridin-2-amine (2):

N'-((3S,4S)-4-((6-amino-4-methylpyridin-2-yl)methyl)pyr
rolidin-3-yl)-N'-(3-(trifluoromethyl)benzyl)ethane-1,2diamine (3):
N'-((3R,4S)-4-((6-amino-4-methylpyridin-2-yl)methyl)pyr
rolidin-3-yl)-N'-phenethylethane-1,2-diamine (4):
N'-((3S,4S)-4-((6-amino-4-methylpyridin-2-yl)methyl)pyr
rolidin-3-yl)ethane-1,2-diamine (5):
N'-((3S,4S)-4-((6-amino-4-methylpyridin-2-yl)methyl)pyr
rolidin-3-yl)-N'-(4-chlorobenzyl)ethane-1,2-diamine (6):
N'-((3S4S)-4-((6-amino-4-methylpyridin-2-yl)methyl)pyr
rolidin-3-yl)-N'-phenethylethane-1,2-diamine (7); and
N'-((3R,4S)-4-((6-amino-4-methylpyridin-2-yl)methyl)pyr
rolidin-3-yl)-N'-(3-fluorophenethyl)ethane-1,2-diamine
(8). (Nomenclature for Such compounds provided using
ChemBioDraw Ultra, version 12.0.2.1076.)
Methods of the present invention can also, as would be
understood by those skilled in the art, be extended to or
include methods using or in conjunction with a pharmaceu
tical composition comprising an inhibitor compound of the
sort described herein and a physiologically or otherwise Suit
able formulation. In a Some embodiments, the present inven
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vention thereof.

The following non-limiting examples and data illustrate
various aspects and features relating to the methods of the
present invention, including the use and administration of
various nitric oxide synthase inhibitor compounds, as are
available through the synthetic methodologies described
herein. In comparison with the prior art, the present methods
provide results and data which are Surprising, unexpected and
contrary thereto. While the utility of this invention is illus
trated through the use of several inhibitor compounds and
related pharmaceutical compositions, it will be understood by
those skilled in the art that comparable results are obtainable
with various other inhibitor compounds and compositions, as
are commensurate with the scope of this invention.
Materials and Methods

50

55

with the various methods described herein, for administration

or contact with a human/animal melanocyte, melanoma cell
and/or a nitric oxide synthase expressed or otherwise present
therein. Whether or not in conjunction with a pharmaceutical
composition, "contacting” means that a nitric oxide synthase
and one or more inhibitor compounds are brought together for
purpose of binding and/or complexing Such an inhibitor com
pound to the enzyme. Amounts of a compound effective to
inhibit a nitric oxide synthase may be determined empirically,
and making Such determinations is within the skill in the art
Inhibition or otherwise affecting nitric oxide synthase activity

pharmaceutical arts. In general, a Suitable dose will be an
amount which is the lowest dose effective to produce a thera
peutic or prophylactic effect. If desired, an effective dose of
Such a compound, pharmaceutically-acceptable salt thereof,
or related composition may be administered in two or more
Sub-doses, administered separately over an appropriate
period of time.
Methods of preparing pharmaceutical formulations or
compositions include the step of bringing an inhibitor com
pound into association with a carrier and, optionally, one or
more additional adjuvants or ingredients. For example, stan
dard pharmaceutical formulation techniques can be
employed. Such as those described in Remington's Pharma
ceutical Sciences, Mack Publishing Company, Easton, Pa.
Regardless of composition or formulation, those skilled in
the art will recognize various avenues formedicament admin
istration, together with corresponding factors and parameters
to be considered in rendering Such a medicament Suitable for
administration. Accordingly, with respect to one or more
non-limiting embodiments, the present invention provides for
use of one or more neuronal nitric oxide synthase inhibitor
compounds for the manufacture of a medicament for thera
peutic use in the treatment of human melanoma or the pre
EXAMPLES OF THE INVENTION

tion includes one or more NOS inhibitors, as set forth above,

formulated into compositions together with one or more
physiologically tolerable or acceptable diluents, carriers,
adjuvants or vehicles that are collectively referred to hereinas
carriers. Compositions Suitable for Such contact or adminis
tration can comprise physiologically acceptable sterile aque
ous or nonaqueous solutions, dispersions, Suspensions or
emulsions. The resulting compositions can be, in conjunction

14
includes both reduction and/or mitigation, as well as elimi
nation of NOS activity and/or nitric oxide production.
It is understood by those skilled in the art that dosage
amount will vary with the activity of a particular inhibitor
compound, disease State, route of administration, duration of

60

Cell Culture: Human melanocytes were isolated from new
born foreskin following the procedure described previously,
and cultured in MCDB153 medium (Sigma, St. Louis, Mo.).
(Yang S., Irani K., Heffron S. E., Jurnak F., Meyskens F. L., Jr.
Alterations in the expression of the apurinicfapyrimidinic
endonuclease-1/redox factor-1 (APE/Ref-1) in human mela
noma and identification of the therapeutic potential of res
veratrol as an APE/Ref-1 inhibitor. Mol. Cancer Ther. 2005;

4:1923-35.) Primary fibroblast cells and keratinocytes were
also isolated from foreskins according to literature proce
dures, and cultured in DMEM medium and EpiLife medium
respectively (<10 passage).
Primary melanoma win3211 cells were cultured in
RPMI1640 with 10% fetal bovine serum (FBS), pennicillin
(100 units/ml)/streptomycin (0.1 mg/ml), and 0.01 mg/mL
insulin. Human metastatic melanoma cell line Lu1205 was

65

cultured in L15/MCDB medium with 10% FBS and penni
cillin/streptomycin. Human metastatic melanoma A375
(ATCC), SK-Mel28 (ATCC), c83-2c, c81-61 and c81-46A
cells were cultured in DMEM or F10 medium respectively;

US 9,090,589 B2
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each supplied with 5% FBS, 5% new born bovine serum, and
penicillin and streptomycin (Yang, Supra).
Mouse melanocytes (Melan-A) were cultured in
RPMI1640 medium supplied with 10% FBS, pennicillin/
streptomycin, 0.1 mM 2-mercaptoethanol, and 200 nMTPA.

16
Assay according to manufacturer's protocol (Oxford Bio
medical Research, Inc., Oxford, Mich.).
UV radiation and cell treatment: Cells were grown to about
70% confluence and media was removed completely for UV

Mouse melanoma cells F5061, F428Ob and F5127 were

10-cm dish of cells and ice cubes were placed next to dishes
for absorbing the heat generated by UVA. UVA or UVB
radiation was performed in a Stratagen crosslinker with peak
wavelength at 350 nm or 312 nm respectively. The UV inten
sity was measured by a radiometer with proper probes. Fresh

established in melanoma lesions developed in HGF/SF trans
genic mouse and were cultured in DMEM medium with 10%
FBS, penicillin/streptomycin.
Reagents and Antibodies: The NO donor DETA/NO (Al
exis Biochemicals.) was dissolved in PBS and used at a con
centration of 100 uM. Resveratrol and curcumin were pur
chased from Sigma Life Sciences, dissolved in DMSO, and
used at a concentration of 50 uM. L-arginine was also ordered
from Sigma and the final concentration used in this study is
2.87 mM. The following primary antibodies were used for
Immunoblotting analysis: JunD, MMP-1, Bcl-2. S-100, and
nNOS (SC-17825) were from Santa Cruz Biotechnology:
C-tubulin or B-actin antibody was from Sigma Life Sciences:
and APE/Ref-1 antibody was from Novus Biologicals. HRP
conjugated anti-mouse and anti-rabbit antibodies were from
Santa Cruz, Biotechnology.
Proliferation analysis: MTT Colorimetric Assay was uti
lized for cell proliferation analysis according to manufactur
er's protocol (Vybrant(R), Molecular Probes, Inc. Eugene,
Oreg.).
Tissue array and IHC staining. A human melanoma tissue
array (ME482) was purchased from U.S. Biomax, Inc. The
tissue array includes matched normal skin tissues, which
were biopsied from the adjacent tissue of each cancer tissue
from individual patients. The HRP-AEC Chromogen staining
kit (R&D Systems) was used to visualize the expression
levels of nNOS. Briefly, the slide was deparaffinized and
rehydrated through a graded series of ethanol. After sequen
tial blockings with Peroxidase/Serum/Avidin/Biotin Block
ing reagents, the slide was incubated with nNOS antibody
(1:500) at 4°C. overnight. Following washes, the secondary
biotinylated anti-mouse antibody (1:200) and HSS-HRP
were sequentially applied for 30 min at room temperature,
and reaction product was visualized with hydrogen peroxide
and AEC as chromogenic Substrate, which revealed a bright
red immunoreactivity. All the samples were counterstained
by Haematoxylin.
Cell Protein Extraction and Western Blot Analysis: Mela
noma cells were collected and lysed as described previously.
(Yang Z. Yang S., Misner B.J., Chiu R. Liu F., Meyskens F.
L., Jr. Nitric oxide initiates progression of human melanoma
via a feedback loop mediated by apurinicfapyrimidinic endo
nuclease-1/redox factor-1, which is inhibited by resveratrol.
Mol. Cancer Ther. 2008; 7:3751-60.) Equal amounts of pro
tein samples were subjected to SDS-PAGE, and transferred to
nitrocellulose membranes. The specific protein was then
detected by the antibodies anti-APE/Ref-1 (1:3500), anti
nNOS, anti-Bcl-2 and anti-MMP-1 (1:1000), anti-AP-1/
JunD and anti-CL-Tubulin or anti-actin (1:1,000) followed by
a chemiluminescence detection reagent (Peirce). Measure
ment of signal intensity on membranes was done using an
imaging densitometer with Multi-Analyst software (Bio
Rad). All data were expressed as fold change of the control
based on the calculation of density values of the specific
protein bands standardized by C.-Tubulin/actin.

radiation. For UVA radiation, 5 ml of PBS was added to one

10

media was added back after radiation and cells were returned

to 37° C. incubator for recovering. For drug treatments,
nNOS inhibitors or resveratrol or curcumin were added into
15

were collected and reconstituted in serum-free medium. Pre

pared cells were added to the upper Matrigel-coated insert.
After 20 hr incubation, cells were fixed and stained with

25

hematoxylin. Membranes were visualized microscopically
and the invading cells on each of triplicate membranes were
counted and averaged for 20 random fields.
Transient Transfection Studies: Small interfering RNA
(siRNA) duplexes directed against NOS1 (nNOS) were pur

chased directly from Sigma-Aldrich (NM 000620). 1x10

30

cells were seeded in a 6-well plate. After 24 hours, the cells
were transfected with nNOS siRNA or control siRNA to give
the final concentration of 60 nmol/L according to the manu
facturer's directions via Lipofectamine (Invitrogen, Inc.).
Thirty hours later, cells were treated with L-arginine.
3-Dimensional Skin Reconstructs: A 3-dimensional skin

reconstruct was achieved using a literature method. (Herlyn
35
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M., Hsu M.Y., Meier F. E., Nesbit M., Hsu J.Y., Van Belle P.

et al. E-cadherin expression in melanoma cells restores kera
tinocyte-mediated growth control and down-regulates
expression of invasion-related adhesion receptors. American
Journal of Pathology. 2000; 156:1515-25.) Epidermal equiva
lents were constructed by mixing metastatic melanoma A375
cells with keratinocytes at ratio of 1:15. Once the epidermus
is adhered to the dermal layer, skin equivalents are then lifted
to the air liquid interface to allow keratinocytes differentia
tion. In term of treatments, L-arginine (2.87 mM) in absence
or presence of nNOS inhibitor cpd 8 (a/k/a JI-11) was added
directly to the culture medium from the lift-up day for 2
weeks. By the end of experiments, the skin equivalents were
fixed and stained with H&E for pathological evaluation.
S-100 staining as a melanocyte biomarker was performed to
visualize and confirm the lesion of melanoma.

Synthesis of novel nNOS inhibitors and the docking
model: The design and syntheses ofnNOS inhibitors useful in
conjunction with this invention have been reported previ
ously. (See, e.g., Ji H., Delker S. L., Li H. Martasek P.
Roman L. J., Poulos T. L., et al. Exploration of the active site
of neuronal nitric oxide synthase by the design and synthesis
of pyrrolidinomethyl 2-aminopyridine derivatives. J. Med.
Chem. 2010; 53:7804-24; and Ji H., Li H., Martasek P.

60

Measurements of intracellular Nitric Oxide levels and

NOS activities: NO was measured as nitrite by interaction
with Griess reagent (Enzo Life Sciences, Lausen, Switzer
land). The absorbance at 548 nm was detected and converted
to nitrite concentrations according to the standard curve. The
NOS activity was analyzed by Ultrasensitive Colorimetric

culture media either 24 hr before radiation or right after
radiation when adding fresh media.
Invasion Assay: The invasiveness of melanoma cells was
assessed on the basis of invasion of cells through Matrigel
coated membrane (BDBiosciences). Briefly, melanoma cells

65

Roman L. J., Poulos T. L., Silverman R. B. Discovery of
highly potent and selective inhibitors of neuronal nitric oxide
synthase by fragment hopping. J. Med. Chem. 2009; 52:779
97.) Among them, without limitation, 8 representative com
pounds were utilized to illustrate a varied range of structures
and related activities (summarized in Table 1, below).
Ki value calculation: Recombinant NOS isozymes over
expressed in E. coli were utilized. (Ji, H., et al., Discovery of
highly potent and selective inhibitors of neuronal nitric oxide
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synthase by fragment hopping.J.Med. Chem..., 2009. 52(3): p.
779-97: Ji, H., et al., Exploration of the active site of neuronal
nitric oxide synthase by the design and synthesis of pyrroli
dinomethyl 2-aminopyridine derivatives. J. Med. Chem.
2010.53(21): p. 7804-24.) Relative enzyme inhibition activ
ity '% vs. Log (inhibitor concentration MI) correlation was
analyzed by Prism using nonlinear regression method togen
erate ICso value. The K value was calculated by ICso K, (1+
SI/K).
Adhesion analysis of human metastatic melanoma A375

18
exhibited a marked elevation of total NOS activities, although

no correlations was evident with the metastasis status of

tested cell lines (FIG. 1D).
Example 2

10

cells to fibroblast cells: A375 cells were added to fibroblast

cell monolayer (FB) and incubated with presence or absence

were also carried out with mouse cells since UVB-induced

of nNOS inhibitors for 1 hour. Non-adhesive cells were

washed away by PBS and MTT reagent was utilized to deter
mine the relative amount of cells that adhered to FB cells,

15

which is calculated as: relative adhesive cell OD value=

(sample OD value (adhesive melanoma cells--FB)-negative
control OD value (FB only)). The mean changes of OD values
with treatments (control is set as 0) represented the relative
effects of compounds on melanoma adhesion.
Statistical Analysis: Data are presented as the meant-SD
from three independent experiments. Student's t test was used
to compare two groups, with a P value of <0.05 considered
statistically significant. All tests were two sided. One-way
ANOVA was performed to study the association between the
nNOS staining scores and disease stages, followed by linear
trend analysis. Linear regression analysis was applied to
study the association between nNOS/iNOS inhibition and
anti-invasion activities of novel synthesized inhibitors. The
coefficient of determination (R) and the p-value were
reported.
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Example 1
NO stress stimulates the proliferation of melanoma cells in
vitro. NO donor DETA/NO (1-N-(2-Aminoethyl)-N-(2-am
monioethyl)aminodiazen-1-ium-1,2-diolate)was utilized to

35

mimic NO stress in cell culture media. As shown in FIG. 1A,

in human primary melanocytes, cell proliferation measured
by the MTT colorimetric assay in a 12-day period was sig
nificantly stimulated by DETA/NO exposure compared to
control. At the end of the experiment, melanocytes incubated
with DETA/NO were still proliferative, while the prolifera
tion of control cells peaked by day 6 and started to drop. When
extending the exposure time of DETA/NO in melanocytes to
10 weeks, it was observed that many foci formed in culture
dishes and cells exhibited notable vertical growth potential:
these foci were sub-cloned and re-seeded in a low density and

40
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showed evidence of continued foci formation. Marked stimu

lation of proliferation was also evident in human metastatic
Lu1205 and SK-Mel28 cells with DETA/NO (100 uM) treat
ment (FIG. 1B). However, such increases were not significant
in primary melanoma win3211 cells.
To explore the effects of UV radiation on NO generation,
primary melanoma win3211 cells were irradiated with UVA

50
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(3 J/cm) or UVB (25 ml/cm) respectively, and whole cell

lysates were collected at different time points. The intracel
lular NO levels detected by the Griess reagent were both
significantly elevated (FIG. 1C); however, the pattern of
induction was different after UVA and UVB. UVB-induced

60

NO generation was rapid (30 minutes), potent, peaked by 4
hours and was gone by 24 hours, while the increase of NO by
UVA radiation was not evident until after 24 hours and lasted
for at least 72 hours.

Employing the Ultrasensitive Colorimetric NOS Assay, it
was demonstrated that compared to immortalized melano
cytes (Mel-ST cells) all tested human melanoma cell lines

nNOS expression is elevated melanoma compared to nor
mal melanocytes, which is sensitive to UV radiation and
growth factors. First, as shown in FIG. 2A, an immunoblot
ting assay revealed that the nNOS expression levels in human
melanoma cell lines were much higher compared to levels in
primary normal human melanocytes. Similar experiments
melanoma in the HGF/SF transgenic mouse melanoma model
is well characterized and recapitulates fairly well the etiology
and histopathology of human melanoma. (Noonan F. P.
Otsuka T., Bang S., Anver M. R., Merlino G. Accelerated
ultraviolet radiation-induced carcinogenesis in hepatocyte
growth factor/scatter factor transgenic mice. Cancer Res.
2000; 60:3738-43.) Three mouse melanoma cell lines estab
lished from the developed lesions have been used as the
screening panel for translational or mechanistic studies.
Similar to human cells, immunoblotting study also showed
marked elevated nNOS expressions compared to normal
mouse melanocytes in vitro, especially in F5061 cells, which
are aggressively tumorigenic and metastatic (FIG. 2B).
Consistent with what was found in vitro, histologic exami
nation and IHC staining revealed that nNOS levels detected in
melanoma biopsies were much higher than that of adjacent
normal skin, and the average staining score of pooled mela
noma samples were increased by 1.9 fold (FIG. 2D, p<0.05).
When grouping melanoma samples based on disease stage, a
trend of increased nNOS staining scores was observed with
melanoma progression in patient biopsies (Trend analysis,
p<0.0001, FIG. 1D). The average score of T4NOMO samples
was 2.56, -2 fold of that of T2NOMO ones (1.33).
Given that UV radiation induced a marked increase in NO

levels, the effects of UV irradiation on nNOS expression were
investigated. Notably, both UVA and UVB treatments effi
ciently induced the expression of nNOS protein, but in dif
ferent time-related patterns (FIG. 2D-E). The induction of
nNOS by UVA lasts much longer (for at least 3 days), while
UVB-induced nNOS peaked by 6 hours and diminished
quickly. Such distinct patterns coincided with NO level
changes after UVA or UVB irradiation, indicating the direct
involvement of nNOS in UV-induced NO production in mela
noma cells.

Interestingly, in normal melanocytes, growth factor bFGF,
which stimulates melanoma growth, induced nNOS expres
sion markedly (FIG. 2F). However, nNOS inductions by
UVB and DETA/NO were not evident in melanocytes (FIG.
2G).
Example 3
nNOS silencing was associated with reduced invasion
potential in metastatic melanoma cells. Using siRNA trans
fection, nNOS was transiently knocked down in two meta
static melanoma cells (A375 and Lu 1205) (FIG. 3A). Immu
noblotting analysis showed that with nNOS depletion, the
expression levels of JunD, MMP-1, APE/Ref-1, and Bcl-2
were significantly reduced. Consistently, it was found that the
invasion potential was also decreased in nNOS-depleted
melanoma cells (FIG. 3B).
Example 4
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Effects of nNOS inhibitor cpd 8 (JI-11) on human mela
noma cells. To explore the anti-melanoma effects of nNOS
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inhibitors, a number of synthesized nNOS inhibitors were
tested. (See, FIG. 8 and Table 1, below.) The candidate com
pounds with lower K/nNOS values exhibited higher binding
affinity and more potent enzyme inhibition. The calculated
values of K(eNOS)/K(nNOS) and K,(iNOS)/K(nNOS))
represented the relative selectivity of nNOS over eNOS or
iNOS, respectively. Among these compounds, cpd 8 (FIG.
4A) exhibits 3,000 fold selectivity for nNOS over eNOS and
840 fold over iNOS. Furthermore, cpd 8 binds tightly to
nNOS and its K(nNOS) is very low (17.7 nM.)
At 1 uM concentration, cpd8 effectively inhibited the NOS
activity in metastatic Lu1205 cells; however, its inhibitory
activity became weakened after 48 hours, Suggesting that the
inhibition of nNOS by cpd 8 is potent but reversible (FIG.
4B). (By comparison, Spermidine trihydrochloride (ST), a
commercially-available nNOS inhibitor, generated a compa
rable inhibition of NOS activity at a concentration of 10 uM.)
Cpd8 does not affect basal nNOS levels of melanoma cells,
even up to a concentration of 200 uM (not shown). However,
at concentrations as low as 1 uM, it effectively inhibited the
induction of nNOS by DETA/NO or UVB radiation treat
ments (FIG. 4C-D). As shown in FIG. 4E, DETA/NO-stimu
lated proliferation was significantly reversed by cpd 8 after 3
days. Similar reduction in cell invasion potential was also
evident by cpd 8 co-treatment with DETA/NO (FIG. 4D).
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noma cells.
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Compounds
1
2
3
4
5
6
7
8

nNOS
O.O14
48
O.21
O.88
O.098
O.O85
O.O24
0.0177

iNOS
4.06
609
13.6
18.2
5.84
8.95
5.4
15

Selectivity

eNOS
28
122
116
123.9
282.9
85.16
78.45
53.4

NOSANOS
290
12.7
64.8
20.7
59.6
105.3
225
847.4

Novel nNOS inhibitors showed promising anti-melanoma
efficiently diminished UVA-induced NO production at 1 uM
concentration. With co-treatment, NO levels in most of the
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sented as 1/K,(nNOS)), an R value of 0.1467 (p=0.3964) was
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L-Arginine significantly enhanced the growth and invasion

Surface.

potency (represented as 1/K,(iNOS)) has produced an R of
obtained.

of human melanoma due to a nNOS-mediated NO stress,

which is effectively inhibited by nNOS inhibitors. As shown
in FIG. 5A, an in vitro matrigel-coated chamber invasion
assay demonstrated that incubating metastatic melanoma
cells with L-arginine (2.87 mM), a NOS substrate, markedly
enhanced the invasion potential, which was efficiently
reversed by co-treatment with nNOS inhibitor cpd 8 (JI-11).
In addition, artificial human skin equivalents were con
structed in a 3D setting, incorporating human metastatic
melanoma cells, kerationcytes, and fibroblast cells on a col
lagen base. As shown in FIG. 5B, after 2-weeks of treatment,
L-arginine significantly promoted melanoma growth com
pared to control and melanoma lesions spread over the epi
dermis layer. Some of these lesions grew deeper and invaded
downward toward the dermal layer. All the lesions were
stained positively for melanocyte marker S-100 (FIG. 5C).
Co-treatment with nNOS inhibitor cpd 8 (2 uM) reversed the
overgrowth induced by L-arginine, and the skin reconstruct
samples looked much like control with a smooth epidermal

with their anti-invasive activities, linear regression analysis
was employed utilizing SAS statistic software. Correlation
analysis of anti-invasion potential and iNOS inhibitory
0.0153 (p=0.7917) and for nNOS inhibition potency (repre

nNOSfiNOS represents the selectivity of nNOS over iNOS, calculated by KiiNOS), Ki 40
(nNOS));
NinosfeNOS represents the selectivity of nNOS over eNOS, calculated by KiceNOS), Ki
(nNOS)

Example 5

samples were reduced to basal levels comparable to that of
control. Treatments with these inhibitors alone also signifi
cantly reduced the invasion potential of metastatic melanoma
A375 cells (FIG. 6B). Furthermore, our adhesion analysis
revealed that short-term treatments with nNOS inhibitors sig
nificantly inhibited L-arginine-stimulated adhesion of meta
static A375 cells to human primary fibroblast cells (FIG. 6C).
Among all the tested inhibitors at the concentration of 2 uM,
cpd 8 exhibited the most potent inhibition of the relative
adhesion compared to L-arginine alone.
To determine whether the inhibitions of nNOS correlated

NOS, eNOS
2OOO
2.5
SS2.4
140.8
2886.7
1OO1.9
3268.8
3017

Example 6
activities. As shown in FIG. 6A, all tested nNOS inhibitors

TABLE 1.
Ki (uM

20
Furthermore, to investigate whether L-arginine-induced
NO generation in melanoma is mediated by nNOS, nNOS
depleted cells were incubated with L-arginine and analyzed
intracellular NO levels. As shown in FIG. 5D, L-arginine
failed to induce NO production in nNOS-depleted melanoma
cells, which indicated that L-arginine-induced NO generation
was predominantly mediated by nNOS, which utilizes L-argi
nine as the substrate. Notably, the induction of NO levels
occurred only after L-arginine exposure was reduced by
nNOS inhibitoricpd8 (FIG.5E). Even up to 50 uM resveratrol
and curcumin (two well-documented iNOS inhibitors) failed
to inhibit the increase of NO by L-arginine in human mela

Notably, cpd 2 (Table 1) showed cytotoxicity in tested
melanoma cell lines (wm3211 and Sk-Mel28), and the ICso
was 5uM and 3.5uM, respectively. Toxicity may be related to
the phenyl group attached to the pyrrolidine Natom since a
homolog of cpd 2 (a/k/a cpd JI-16, which is the same as cpd
2 except the phenyl group is absent) does not exhibit any
toxicity in melanoma cells even up to 50 uM (See, FIG. 7).
We claim:
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1. A method of reducing expression of neuronal nitric
oxide synthase, said method comprising:
providing a compound selected from compounds of a for
mula
R2

55

N

T
N

HN
60

65

N

71S-1

N

HR,
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wherein R is selected from H., halogen, methyl and halom
ethyl moieties; R is selected from H, alkyl and haloalkyl
moieties; Z is selected from O and NH; and R is selected
from H. alkyl, halogen and haloalkyl moieties, and salts
thereof, and
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contacting said compound with a cellular medium com
prising one of human melanocytes, melanoma cells and
a combination thereof, said compound in an amount
sufficient to reduce induction of neuronal nitric oxide

synthase expression, thereby reducing ultra-violet
induced nitric oxide production in a human melanocyte

5

selected from cis and trans Stereoisomers.

or melanoma cell.

2. The method of claim 1 wherein R is H, Z is NH, and R.
is selected from H and halogen moieties, said compound
selected from cis and trans Stereoisomers.
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selected from

amine (8),
4. The method of claim 1 wherein said compound is an
ammonium salt.
5. The method of claim 4 wherein said ammonium salt has

a counter ion that is a conjugate base of a protic acid.
6. The method of claim 1 wherein said compound is pro
vided in a pharmaceutical composition.

11. The method of claim 10 wherein said compound is
provided in a pharmaceutical composition.
12. The method of claim 7 wherein said compound is
selected from

3. The method of claim 2 wherein said compound is

N'-((3R,4R)-4-((6-amino-4-methylpyridin-2-yl)methyl)
pyrrolidin-3-yl)-N'-(3-fluorophenethyl)ethane-1,2-di
amine (1):
N'-((3S4S)-4((6-amino-4-methylplyridin-2-yl)methyl)
pyrrolidin-3-yl)-N'-(4-chlorobenzyl)ethane-1,2-di
amine (6):
N'-((3S4S)-4-S(6-amino-4-methylpyridin-2-yl)methyl)
pyrrolidin-3-yl)-N'-phenethylethane-1,2-diamine (7);
and
N'-((3R,4S)-4-((6-amino-4-methylpyridin-2-1)methyl)
pyrrolidin-3-yl)-N'-(3- fluorophenethyl)ethane-1,2-di
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7. The method of claim 1 wherein R is selected from Hand
methyl.
8. The method of claim 7 wherein R is Hand Z is NH.
9. The method of claim 8 wherein R is selected from Hand
halogen moieties.
10. The method of claim 9 wherein said compound is
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N'-((3R,4R)-4-((6-amino-4-methylpyridin-2-yl)pyrroli
din-3-yl)-N'-(3-fluorophenethyl)pethane-1,2-diamine
(1):
N-((3S4S)-4-((6-amino-4-methylpyridin-2-yl)methyl)
pyrrolidin-3-yl)-N'-(4-chlorobenzyl)ethane-1,2-di
amine (6):
N'-((3S4S)-4-((6-amino-4-methylpyridin-2-yl)methyp
pyrrolidin-3-yl)-N'-phenethylethane-1,2-diamine (7):
and
N'-((3R,4S)-4-((6-amino-4-methylpyridin-2-yl)methyl)
pyrrolidin-3-yl)-N'-(3- fluorophenethyl)ethane-1,2-di
amine (8).
13. The method of claim 12 wherein said compound is an
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ammonium salt.
14. The method of claim 13 wherein said ammonium salt

has a counter ion that is a conjugate base of a protic acid.
15. The method of claim 14 wherein said compound is
provided in a pharmaceutical composition.
k

k

k

k

k

